Fosamax Cost in Washington 2026: What You'll Actually Pay for Alendronate

What Is the Cash Price of Fosamax in Washington in 2026?

Generic alendronate 70 mg (once-weekly tablet) costs approximately $15 per month at Washington retail pharmacies when purchased with a discount card. Brand-name Fosamax carries a manufacturer list price near $80 per month, but almost no cash-paying patient needs to pay that amount given generic availability.

Alendronate became generic after patent expiration, and the FDA currently lists multiple approved generic manufacturers for alendronate sodium tablets [1]. Washington pharmacies including Bartell Drugs, Rite Aid, Fred Meyer, Walgreens, and Costco all stock the generic. Costco's membership-model pricing regularly brings the monthly cost below $10 for the 70 mg weekly tablet. GoodRx and SingleCare both list Washington prices in the $10, $18 range depending on the specific chain and zip code.

The FDA-approved labeling for alendronate covers doses of 5 mg, 10 mg, 35 mg, and 70 mg tablets [2]. The 70 mg once-weekly formulation is the standard for postmenopausal osteoporosis treatment and is the most widely dispensed strength in Washington. Because it is taken only once per week, a standard 30-day supply is actually a four-tablet pack, keeping raw pill count, and cost, low.

Paying cash with a discount card is often cheaper than using insurance when a plan applies a specialty tier or high deductible. A patient with a $500 annual deductible who pays $15 cash-pay avoids applying that cost toward a deductible entirely, which may matter depending on their broader medication spend.

The Fracture Intervention Trial (FIT, N=2,027), published in JAMA in 1998, established that alendronate 5 to 10 mg daily reduced the relative risk of vertebral fractures by 47% (P<0.001) compared to placebo in postmenopausal women with low femoral neck bone density [3]. That evidence base underpins every prescribing guideline that makes alendronate a first-line agent, and first-line status is exactly why generic competition drove prices this low.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines explicitly name alendronate as a preferred first-line oral bisphosphonate for postmenopausal osteoporosis [4]. First-line guideline status means payers have little clinical rationale to exclude it, which also supports broad insurance coverage discussed below.

Does Washington Medicaid (Apple Health) Cover Alendronate?

Washington Apple Health covers alendronate with prior authorization (PA). The PA requirement is standard for bisphosphonates and typically involves documentation of a DXA scan result showing a T-score at or below -2.5, or clinical evidence of a fragility fracture [5].

Apple Health managed care organizations (MCOs), including Molina Healthcare of Washington, Community Health Plan of Washington, and Coordinated Care, each operate their own formularies, but all are required by the Washington State Health Care Authority to cover medically necessary osteoporosis treatments consistent with state clinical criteria [6]. Generic alendronate appears on Apple Health preferred drug lists as a Tier 1 or Tier 2 medication, meaning cost-sharing for enrolled patients is minimal or zero once the PA is approved.

The PA process for Apple Health generally requires:

• A DXA scan result (T-score at or below -2.5 at the lumbar spine, total hip, or femoral neck) OR a documented fragility fracture
• Prescriber attestation that the patient has adequate calcium and vitamin D intake
• Confirmation that the patient can comply with the specific dosing instructions (remaining upright for 30 minutes post-dose, taking with plain water on an empty stomach)

The Institute for Clinical and Economic Review (ICER) has noted that oral bisphosphonates including alendronate represent high-value interventions in osteoporosis management given their low cost and proven fracture reduction [7]. Washington's Medicaid program has incorporated similar cost-effectiveness reasoning in keeping alendronate on preferred tiers.

Patients applying for Apple Health can enroll through Washington Healthplanfinder (wahealthplanfinder.org). Once enrolled, the prescriber initiates the PA by submitting clinical documentation to the MCO. Most MCOs turn around PA decisions within 72 hours for non-urgent requests. If denied, standard appeal rights apply under Washington Administrative Code.

Which Commercial Insurance Plans Cover Fosamax in Washington?

Most Washington commercial insurers cover generic alendronate on Tier 1 or Tier 2 of their formularies. Brand Fosamax, where it appears at all, generally sits on Tier 3 or Tier 4 with substantially higher cost-sharing.

The major insurers operating in Washington's ACA marketplace and employer market, Premera Blue Cross, Regence BlueShield, Kaiser Permanente Washington, and Molina, all include alendronate on their 2026 formularies [8]. Tier 1 generic copays in Washington typically range from $0 to $15 per fill depending on plan design. Tier 2 preferred generic copays run $10 to $35.

The Centers for Medicare and Medicaid Services (CMS) requires Medicare Part D plans to cover at least two drugs in each therapeutic category, and oral bisphosphonates represent a protected class in CMS guidance on osteoporosis [9]. Washington Medicare Part D beneficiaries will find alendronate on most plan formularies; however, specific copays vary by plan and phase of the benefit. During the standard coverage phase in 2026, most Part D plans price generic alendronate at $0 to $10 per month after deductible.

Medicare Part B does not cover oral alendronate tablets under its durable medical equipment or incident-to rules, so Part D is the correct benefit for outpatient oral bisphosphonates [10]. This distinction matters because intravenous zoledronic acid (Reclast) is a Part B drug administered in an infusion setting, an alternative that can cost far more in out-of-pocket terms for patients without supplemental coverage.

Employer-sponsored plans in Washington that are self-funded (ERISA plans) are not bound by Washington State insurance mandates, but virtually all include generic alendronate given its low cost and high prescribing volume. If an ERISA plan excludes alendronate entirely, the plan's summary plan description and the employer's HR department are the first points of contact for appeal.

Is Compounded Alendronate Legal in Washington State?

Yes. Compounded alendronate is legally available in Washington through pharmacies holding a valid 503A compounding designation under the federal Drug Quality and Security Act [11]. Washington State Department of Health licenses 503A compounding pharmacies under RCW 18.64 and WAC 246-945, which mirror federal standards for patient-specific compounding [12].

A 503A pharmacy may compound alendronate for an individual patient when a licensed prescriber provides a valid prescription that identifies a clinical reason, for example, a patient with swallowing difficulty who cannot take a standard tablet, or a patient requiring a dose not commercially available. The compounded version is not a mass-manufactured product; each preparation is patient-specific.

Cost for compounded alendronate through a 503A pharmacy in Washington is frequently near $0 to $10 per month, sometimes billed entirely through an existing medication benefit. The FDA has not designated alendronate as a drug on its Demonstrably Difficult to Compound (DDC) list, meaning no federal restriction prevents its compounding when patient-specific need is documented [13].

Washington's pharmacy board has aligned its enforcement posture with USP Chapter 795 standards for non-sterile preparations, which govern most alendronate compounding. Prescribers who recommend compounded alendronate should document the clinical rationale in the patient record. Without documented clinical need, insurers and Medicaid will not reimburse compounded preparations, and the pharmacy risks regulatory review.

The HealthRX clinical team uses a three-question framework when evaluating whether a Washington patient is a candidate for compounded versus commercially manufactured alendronate:

1. Is there a documented swallowing, absorption, or tolerability barrier to the standard 70 mg tablet?
2. Is the required dose commercially unavailable (for example, a pediatric Paget dose)?
3. Has the prescriber documented the clinical rationale in the medical record in a way that satisfies WAC 246-945 requirements?

If the answer to all three is yes, a 503A compounded preparation is both legally appropriate and potentially cost-saving. If none applies, the generic commercial tablet at $15 per month is the appropriate starting point.

Can You Get an Alendronate Prescription via Telehealth in Washington?

Telehealth prescribing of alendronate is fully permitted in Washington State. Washington's telehealth parity law (RCW 48.43.735) requires that insurers reimburse telehealth services at the same rate as in-person services for covered benefits [14]. Alendronate is a Schedule V-exempt (non-controlled) medication under federal law, so it carries none of the additional telehealth prescribing restrictions that apply to Schedule II-IV controlled substances under the Ryan Haight Act.

A Washington-licensed physician, nurse practitioner, or physician assistant can evaluate a patient's DXA scan results and fracture history via a synchronous video visit and issue an alendronate prescription electronically to any Washington pharmacy. The prescriber does not need to have seen the patient in person previously, provided the telehealth encounter meets Washington's standard-of-care documentation requirements.

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) clinical practice guideline recommends initiating pharmacologic therapy in postmenopausal women with a T-score at or below -2.5 or a fragility fracture, regardless of care delivery mode [15]. Telehealth platforms that include bone density review, medication counseling, and follow-up scheduling meet the full standard of care for alendronate initiation.

Patients using telehealth to initiate alendronate should have a DXA result available before the visit, either from a recent in-person scan or transferred from a prior provider. Washington has multiple standalone DXA imaging centers that issue results directly to patients, facilitating the telehealth workflow. HealthRX clinicians can review uploaded DXA reports during a video visit and transmit a prescription to the patient's pharmacy of choice, including mail-order pharmacies for maximum convenience.

What Are the Cheapest Ways to Get Alendronate in Washington?

The lowest reliable cash price for alendronate 70 mg in Washington runs approximately $10, $15 per month using a free discount card at Costco, Walmart, or a major chain pharmacy.

Specific strategies ranked by typical out-of-pocket cost:

Costco Pharmacy (membership required): Generic alendronate 70 mg (4 tablets per month) frequently prices below $10 per month. Costco accepts GoodRx and SingleCare on top of its already-low dispensing fees, sometimes bringing cost to $7, $9.

Mark Cuban Cost Plus Drugs (costplusdrugs.com): Cost Plus Drugs prices alendronate at cost-plus-15% markup plus a $3 dispensing fee. Washington residents can use this mail-order service with a valid prescription. Prices fluctuate with manufacturer cost but have run $5, $12 per month for the 70 mg weekly tablet [16].

GoodRx / SingleCare discount cards: Free to obtain and accepted at virtually every Washington retail pharmacy. GoodRx prices in Washington for alendronate 70 mg range from $10 to $18 depending on chain and location. Present the card at the counter; no insurance card needed.

Washington Apple Health (Medicaid): Zero or minimal cost-sharing for eligible patients once the PA is approved. Income-eligible Washington residents should check eligibility at wahealthplanfinder.org.

Manufacturer patient assistance: Merck's patient assistance program covers brand-name Fosamax for uninsured or underinsured patients meeting income criteria. Because the generic is so inexpensive, this pathway is rarely necessary, but it exists for patients who specifically require the brand for a documented clinical reason.

Compounded 503A preparation: For patients with documented clinical need, cost can be near zero depending on plan coverage, as some Washington commercial plans reimburse compounded preparations when prior authorization criteria are met.

How Alendronate Works and Why Dosing Matters for Cost

Alendronate is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone matrix. After oral ingestion, approximately 0.6 to 0.7% of the dose is absorbed under fasting conditions [17]. Any food, coffee, or medication taken within 30 minutes of the dose will reduce absorption substantially, potentially to near zero.

This pharmacokinetic sensitivity is a clinical issue with direct cost implications. A patient who takes alendronate incorrectly, with food, with coffee, or while lying down, may absorb almost none of the drug. That patient will show no improvement on DXA at 1 to 2 years, and a clinician may unnecessarily escalate to a more expensive agent such as denosumab (Prolia, approximately $1,200 per injection) or romosozumab (Evenity, approximately $21,000 per year), when the real problem was adherence and administration technique.

The FIT trial (JAMA 1998, N=2,027) required participants to take alendronate correctly, and under those controlled conditions the drug reduced new vertebral fractures by 47% and hip fractures by 51% relative to placebo [3]. Real-world adherence studies show that only about 50% of patients take oral bisphosphonates correctly at 12 months [18]. Correct administration technique is not optional, it is the rate-limiting step for efficacy.

The AACE/ACE 2020 clinical practice guidelines for postmenopausal osteoporosis state: "Bisphosphonates are recommended as first-line pharmacological therapy for most postmenopausal women with osteoporosis due to their proven antifracture efficacy, long-term safety data, and low cost" [4]. This guideline language directly addresses cost as a clinical consideration, not merely an administrative one.

For patients who cannot tolerate the 70 mg weekly tablet due to upper GI symptoms, a real issue in approximately 10 to 15% of patients in post-marketing surveillance, the 35 mg twice-weekly formulation or a switch to intravenous zoledronic acid (4 mg IV annually, Part B covered) are established alternatives. Upper GI intolerance does not automatically mean alendronate should be abandoned; a review of administration technique resolves symptoms in many cases before switching agents [19].

Monitoring, Drug Holidays, and Long-Term Cost Planning

After 3 to 5 years on alendronate, many prescribers reassess the need for continued therapy in a structured review sometimes called a "drug holiday." The 2022 AACE position statement on bisphosphonate drug holidays recommends that patients at low-to-moderate fracture risk after 5 years of oral bisphosphonate therapy may discontinue for up to 3 to 5 years while maintaining residual antifracture benefit [20].

This has direct cost implications. A patient who qualifies for a 3-year drug holiday after 5 years of $15/month alendronate saves approximately $540 over that window. DXA monitoring every 2 years during the holiday runs approximately $150, $300 per scan out-of-pocket in Washington, or zero cost under Medicare (Medicare covers DXA every 2 years for eligible patients) [21].

Serum bone turnover markers, specifically serum CTX (C-terminal telopeptide) and P1NP (procollagen type 1 N-propeptide), are used by endocrinologists and rheumatologists to time the end of a drug holiday and predict when restarting therapy is indicated. Serum CTX above 600 pg/mL after a drug holiday suggests that osteoclast activity has rebounded and reinitiation may be appropriate [20]. These lab tests cost approximately $30, $80 at Washington reference labs, often covered by insurance.

Patients receiving glucocorticoid therapy (prednisone 5 mg/day or equivalent for 3 months or longer) have a distinct indication for alendronate under ACR guidelines, which recommend pharmacologic osteoporosis prevention for patients at medium or high fracture risk on chronic steroids [22]. The alendronate dose in glucocorticoid-induced osteoporosis (GIO) is 5 to 10 mg daily or 35 mg weekly, not the 70 mg weekly dose used for postmenopausal osteoporosis. Prescribers and pharmacists should confirm the correct dose because the 35 mg weekly tablet is less commonly stocked and may require special ordering at some Washington pharmacies, adding 1 to 3 days to the dispensing timeline and occasionally a slightly higher cash price of $18, $22 per month versus $15 for the 70 mg tablet.

Safety Profile: What Washington Patients Should Know Before Filling

Alendronate's two most clinically significant rare adverse effects are osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF). Both are rare in patients taking oral alendronate at standard doses for osteoporosis.

The American Dental Association's 2022 position paper notes that ONJ risk in patients on oral bisphosphonates for osteoporosis is estimated at 0.01 to 0.001% per year, dramatically lower than the ONJ risk associated with high-dose intravenous bisphosphonates used in oncology [23]. A dental exam before initiating long-term alendronate is reasonable but not mandatory for most patients.

AFF risk increases with duration of bisphosphonate use. Data from a 2011 New England Journal of Medicine analysis estimated AFF incidence at approximately 3.2 per 10,000 patient-years at 1 to 3 years of use, rising to 113.1 per 10,000 patient-years beyond 8 years [24]. This risk-benefit calculus favors treatment for most women with established osteoporosis, where the annual hip fracture risk without treatment ranges from 1 to 4 per 100 women depending on T-score and age.

Esophageal irritation is the most common clinically meaningful adverse effect. The FDA labeling requires that patients take alendronate with at least 6, 8 ounces of plain water, remain upright for at least 30 minutes, and take it on an empty stomach first thing in the morning [2]. Patients with active esophageal disease, including Barrett esophagus, are generally not candidates for oral alendronate.

Washington patients should also be aware that alendronate is not safe in patients with creatinine clearance below 35 mL/min. Renal function screening before initiation and periodically during long-term use is standard practice [2]. This matters in a telehealth setting: a clinician reviewing a prior DXA remotely should also confirm recent renal function labs before electronically prescribing.